The DECAF trial: coffee, caffeine, and atrial fibrillation

Cardiovascular Research · Published 2026-07-04 · DOI 10.1093/cvr/cvag155

Authors (2)

Christopher X Wong, Gregory M Marcus

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wong, C., Marcus, G. (2026). The DECAF trial: coffee, caffeine, and atrial fibrillation. Cardiovascular Research. https://doi.org/10.1093/cvr/cvag155

Related articles

• Urea cycle fumarate limits fibrosis post-myocardial infarction by reducing fibroblast mitochondrial adenosine triphosphate production · Cardiovascular Research · 2026 · Same journal
• Immunomodulatory endothelial cells contribute to T-cell recruitment and activation via antigen presentation on MHC II · Cardiovascular Research · 2026 · Same journal
• PKC-PKD-NFκB signalling induces cardiomyocyte t-tubule loss via a conserved macropinocytic mechanism · Cardiovascular Research · 2026 · Same journal
• Loss of caveolar A1 adenosine receptor signalling blunts anti-adrenergic control in heart failure · Cardiovascular Research · 2026 · Same journal
• Metabolic crisis and TRPM4 activation cause QT prolongation in TANGO2 deficiency disorder · Cardiovascular Research · 2026 · Same journal
• A titin truncating variant linked to atrial fibrillation increases atrial profibrotic signalling and cholinergic sensitivity · Cardiovascular Research · 2026 · Same journal
• Plasma proteomics maps molecular bridges from depression to incident CHD: 15-year proteomic trajectories and enhanced prediction · Cardiovascular Research · 2026 · Same journal
• Machine learning-guided risk stratification for long QT syndrome genetic variants with hiPSC-derived cardiomyocytes · Cardiovascular Research · 2026 · Same journal
• Restraining fibrosis in cardiac repair · Cardiovascular Research · 2026 · Same journal
• Neural resilience improves survival in cardiovascular patients · Cardiovascular Research · 2026 · Same journal